雾化利多卡因在新型冠状病毒肺炎中的应用假说
Nebulized Lidocaine in COVID-19, An Hypothesis.
作者信息
Ali Ziad A, El-Mallakh Rif S
机构信息
Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, 401 East Chestnut Street, Suite 610, Louisville, KY 40202, United States.
出版信息
Med Hypotheses. 2020 Nov;144:109947. doi: 10.1016/j.mehy.2020.109947. Epub 2020 Jun 1.
Abstract
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients' lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.
摘要
2019冠状病毒病（COVID-19）已在全球范围内大规模爆发，并被世界卫生组织（WHO）宣布为大流行病。有人提出，与COVID-19相关的过度炎症和免疫反应失调可能在引发细胞因子风暴中起关键作用，而细胞因子风暴通常会使感染者发展为危及生命的急性肺损伤或急性呼吸窘迫综合征。利多卡因是一种局部镇痛药和抗心律失常药，以其抗炎作用而闻名，已被用于减轻重度哮喘患者的咳嗽并改善呼吸症状。它具有已证实的安全性。有人提出，雾化利多卡因作为对抗新型冠状病毒患者严重呼吸道症状的辅助治疗，通过吸入给药时，可能有助于减少细胞因子、保护患者肺部并改善COVID-19患者的预后。有必要进行进一步研究。
相似文献
1
Nebulized Lidocaine in COVID-19, An Hypothesis.雾化利多卡因在新型冠状病毒肺炎中的应用假说
Med Hypotheses. 2020 Nov;144:109947. doi: 10.1016/j.mehy.2020.109947. Epub 2020 Jun 1.
2
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.基于嘌呤能信号转导的新型 COVID-19 过度炎症反应定义和治疗方法。
Purinergic Signal. 2022 Mar;18(1):13-59. doi: 10.1007/s11302-021-09814-6. Epub 2021 Nov 10.
3
AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.抗 miRNA：治疗 COVID-19 细胞因子风暴的新策略。
Cytokine Growth Factor Rev. 2021 Apr;58:111-113. doi: 10.1016/j.cytogfr.2020.09.001. Epub 2020 Sep 9.
4
Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.固有受体激活模式涉及 COVID-19、ALI/ARDS 和脓毒症细胞因子风暴中的 TLR 和 NLR 协同作用：综述和模型制作新的预测和治疗建议。
Int J Mol Sci. 2021 Feb 20;22(4):2108. doi: 10.3390/ijms22042108.
5
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.托珠单抗治疗 COVID-19 诱导的细胞因子风暴和急性呼吸窘迫综合征：来自宾夕法尼亚州西部农村一级创伤中心的病例系列。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211019557. doi: 10.1177/23247096211019557.
6
in COVID-19 Infection: Immunopathogenesis and Possible Therapeutic Perspective.在 COVID-19 感染：免疫发病机制和可能的治疗视角中。
Viral Immunol. 2021 Dec;34(10):679-688. doi: 10.1089/vim.2021.0071. Epub 2021 Dec 8.
7
The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.新冠病毒引发的急性呼吸窘迫综合征的时间治疗学疗法。
Br J Pharmacol. 2020 Nov;177(21):4845-4850. doi: 10.1111/bph.15140. Epub 2020 Jul 3.
8
IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19.白细胞介素-17A和肿瘤坏死因子-α作为肥胖合并新型冠状病毒肺炎患者急性呼吸窘迫综合征和死亡率的潜在生物标志物。
Med Hypotheses. 2020 Nov;144:109935. doi: 10.1016/j.mehy.2020.109935. Epub 2020 Aug 7.
9
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
10
Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.儿童系统性红斑狼疮合并急性呼吸窘迫综合征及 COVID-19。
Lupus. 2021 Apr;30(5):836-839. doi: 10.1177/0961203321989791. Epub 2021 Jan 28.
引用本文的文献
1
Lidocaine Affects Collagen Breakdown Without Compromising Cell Viability in Cultured Human Tenocytes: An In Vitro Study.利多卡因影响培养的人肌腱细胞中的胶原蛋白分解而不损害细胞活力：一项体外研究。
Cells. 2025 Jun 27;14(13):988. doi: 10.3390/cells14130988.
2
"Nebulized lidocaine for intractable cough in hospice care: a comprehensive review of efficacy, safety, and future perspectives".雾化利多卡因用于临终关怀中难治性咳嗽：疗效、安全性及未来展望的全面综述
BMC Palliat Care. 2025 Apr 30;24(1):123. doi: 10.1186/s12904-025-01752-z.
3
Changes in the skeletal muscle transcriptome due to the intramuscular administration of lidocaine in wether lambs.去势羔羊肌肉注射利多卡因后骨骼肌转录组的变化
J Anim Sci. 2025 Jan 4;103. doi: 10.1093/jas/skaf116.
4
Ribonucleic Acid Sequencing Reveals the Upregulation and Resolution of Inflammation and Extracellular Matrix Remodeling in Lidocaine-Treated Human Acute Monocytic Leukemia Cell Line THP-1.核糖核酸测序揭示利多卡因处理的人急性单核细胞白血病细胞系THP-1中炎症的上调与消退及细胞外基质重塑
Biomedicines. 2024 Feb 23;12(3):509. doi: 10.3390/biomedicines12030509.
5
Clinical dosage of lidocaine does not impact the biomedical outcome of sepsis-induced acute respiratory distress syndrome in a porcine model.临床剂量的利多卡因不会影响猪模型中脓毒症诱导的急性呼吸窘迫综合征的生物医学结局。
PeerJ. 2023 Aug 21;11:e15875. doi: 10.7717/peerj.15875. eCollection 2023.
6
The Effect of Local Anesthetics on Neutrophils in the Context of Different Isolation Techniques.不同分离技术背景下局部麻醉药对中性粒细胞的影响。
Biomedicines. 2023 Aug 2;11(8):2170. doi: 10.3390/biomedicines11082170.
7
An Approach to Acute SARS-CoV-2 Management with Complementary Neuraltherapeutic Medicine: A Case Report.一种采用辅助神经治疗医学管理急性SARS-CoV-2感染的方法：病例报告
Clin Med Insights Case Rep. 2023 Apr 5;16:11795476231159584. doi: 10.1177/11795476231159584. eCollection 2023.
8
Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.肺部药物递送：抗击 COVID-19 的有效且便捷的给药途径。
Drug Deliv Transl Res. 2023 Mar;13(3):705-715. doi: 10.1007/s13346-022-01251-1. Epub 2022 Oct 19.
9
A case report of an 18-year-old receiving nebulized lidocaine for treatment of COVID-19 cough.一篇关于 18 岁患者使用雾化利多卡因治疗 COVID-19 咳嗽的病例报告。
Heart Lung. 2023 Jan-Feb;57:140-143. doi: 10.1016/j.hrtlng.2022.09.009. Epub 2022 Sep 22.
10
The Effects of HS and Recombinant Human Hsp70 on Inflammation Induced by SARS and Other Agents In Vitro and In Vivo.高渗盐水和重组人热休克蛋白70对严重急性呼吸综合征及其他病原体在体内外诱导炎症的影响
Biomedicines. 2022 Sep 1;10(9):2155. doi: 10.3390/biomedicines10092155.
本文引用的文献
1
An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.一种用于管理在接受氯喹或羟氯喹联合阿奇霉素治疗的2019冠状病毒病（COVID-19）患者中QT间期延长的算法：静脉注射利多卡因的潜在益处
HeartRhythm Case Rep. 2020 Apr 1;6(5):244-248. doi: 10.1016/j.hrcr.2020.03.016. eCollection 2020 May.
2
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.抗炎药物在治疗重症新型冠状病毒病 2019（COVID-19）患者中的应用：来自中国临床免疫学家的观点。
Clin Immunol. 2020 May;214:108393. doi: 10.1016/j.clim.2020.108393. Epub 2020 Mar 25.
3
COVID-19 infection: the perspectives on immune responses.新型冠状病毒肺炎感染：免疫反应的观点
Cell Death Differ. 2020 May;27(5):1451-1454. doi: 10.1038/s41418-020-0530-3. Epub 2020 Mar 23.
4
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
5
WHO Declares COVID-19 a Pandemic.世界卫生组织宣布新冠疫情为大流行病。
Acta Biomed. 2020 Mar 19;91(1):157-160. doi: 10.23750/abm.v91i1.9397.
6
Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review.新型冠状病毒病（COVID-19）在早期暴发期间的流行病学、病因、临床表现和诊断、预防和控制：范围综述。
Infect Dis Poverty. 2020 Mar 17;9(1):29. doi: 10.1186/s40249-020-00646-x.
7
Lidocaine during intubation and extubation in patients with coronavirus disease (COVID-19).新型冠状病毒肺炎（COVID-19）患者插管和拔管期间使用利多卡因的情况。
Can J Anaesth. 2020 Jun;67(6):759. doi: 10.1007/s12630-020-01627-2. Epub 2020 Mar 16.
8
Treatment of COVID-19: old tricks for new challenges.2019冠状病毒病的治疗：应对新挑战的老办法
Crit Care. 2020 Mar 16;24(1):91. doi: 10.1186/s13054-020-2818-6.
9
The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia.与严重和危重新冠肺炎相关的临床和胸部 CT 特征。
Invest Radiol. 2020 Jun;55(6):327-331. doi: 10.1097/RLI.0000000000000672.
10
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
Zotero 插件